Skip to main content
S&P 5007,781.32-0.26%DOW51,067.93-0.22%NASDAQ27,400.88-0.50%BTC$81,308.00-2.66%ETH$2,431.75-5.37%GOLD$4,143.90+0.08%OIL$91.00+3.08%
Smart Investors Daily
SID Premium
IB

AMEX · IBO

Impact BioMedical Inc.

Healthcare · Biotechnology

$4.48

Down-$0.28 (-6.25%)

Updated Oct 8, 2026, 4:33 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.1M
P/E ratio
-0.15
Dividend yield
0.00%
52-week range
$0.37 – $7.70
Volume
10.74K
Avg. volume
143.99K

Price performance · IBO

IBO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

IBO closed at $4.48 after 21 trading sessions, up 807.43% for the selected period.

Last close
$4.48
Period change
+807.43%
Period low
$0.44
Period high
$7.45
Daily close
View OHLC price history
IBO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$4.57$4.59$4.36$4.4810.74K
Oct 6, 2026$5.00$5.05$4.43$4.6821.17K
Oct 5, 2026$5.16$5.42$4.84$4.8417.34K
Oct 2, 2026$5.54$5.54$5.265$5.320111.55K
Oct 1, 2026$5.88$5.88$5.43$5.438.99K
Sep 30, 2026$5.48$5.75$5.48$5.603.93K
Sep 29, 2026$5.50$6.17$5.43$5.609.04K
Sep 28, 2026$5.69$6.0231$5.5904$5.619.27K
Sep 25, 2026$5.80$6.4999$5.58$5.6920.65K
Sep 24, 2026$6.86$6.86$5.51$5.6523.37K
Sep 23, 2026$6.46$7.11$5.62$6.6340.52K
Sep 22, 2026$7.0016$7.0016$6.6583$6.658312.27K
Sep 21, 2026$7.4458$7.5316$6.9423$7.01297.22K
Sep 18, 2026$7.2111$7.4458$6.9423$7.44587.74K
Sep 17, 2026$6.5851$7.6982$6.5851$7.211120.25K
Sep 16, 2026$0.54$0.547$0.498$0.498164.69K
Sep 15, 2026$0.48$0.5489$0.4785$0.529121.75K
Sep 14, 2026$0.4521$0.5179$0.4521$0.4841113.01K
Sep 11, 2026$0.4467$0.49$0.4467$0.4602310.59K
Sep 10, 2026$0.475$0.5082$0.4337$0.441272.46K
Sep 9, 2026$0.509$0.51$0.4818$0.493749.15K

Latest IBO news

The latest Smart Investors Daily articles mentioning IBO.

Stock researchCompany · Overview

IBO research

Overview

Company profile and research snapshot.

Company profile

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.

Yahoo · Sep 16, 2026

Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) (“Z

Yahoo · Sep 15, 2026

CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)

HOUSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- This corrected press release is being issued to correct the merger exchange ratio that was incorrectly stated in the press release of Impact Biomedical Inc. (the “Company” or “Impact”) dated September 11, 2026. The original press release incorrectly stated that Impact stockholders would receive one (1) share of Zoar Limited for every four (4) shares of Impact Common Stock (defined below). The correct exchange ratio, as set forth in the Merger and Share

Yahoo · Sep 11, 2026

Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)

HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (the “Company”) today announced that the Company's Board of Directors has approved a 1 for 12.62 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock"). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE Am

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By